| Name | Title | Contact Details |
|---|
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.
The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...
Pioneering solutions for targeted and controlled bone healing. Join us in our mission to eliminate non-unions and improve patient rehabilitation.